克莱恩将出席Cantor Fitzgerald年度全球医疗保健大会-动脉网

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

BioSpace 等信源发布 2023-09-25 20:20



可切换为仅中文







SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, today announced that it will participate in the Cantor Fitzgerald Annual Global Healthcare Conference.

2023年9月25日盐湖城（GLOBE NEWSWIRE）-Clene Inc.（纳斯达克股票代码：CLNN）（及其子公司“Clene”）及其合资子公司Clene Nanomedicine Inc.，一家临床后期生物制药公司专注于改善线粒体健康和保护神经元功能，以治疗神经退行性疾病，包括肌萎缩侧索硬化症，帕金森病，和多发性硬化症，今天宣布将参加Cantor Fitzgerald年度全球医疗保健会议。

Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will be participating in the presentation and 1x1 investor meetings..

首席执行官Rob Etherington和首席财务官Morgan Brown将参加演讲和1x1投资者会议。。

Dates: September 26-28, 2023

日期：2023年9月26日至28日

Location: InterContinental Barclay Hotel, New York, NY

地点：InterContinental Barclay Hotel，New York，NY

Date and Time of Presentation: September 26, 2023, at 1:35 p.m. ET

演讲日期和时间：2023年9月26日下午1:35

Format: Presentation and 1x1 meetings

格式：演示文稿和1x1会议

A webcast of the presentations, if available, will be available on the “Events” section of the Clene website or you can register at the following link to view the webcast: https://wsw.com/webcast/cantor19/clnn/2087547

演示文稿的网络广播（如果有）将在Clene网站的“事件”部分提供，或者您可以在以下链接注册以查看网络广播：https://wsw.com/webcast/cantor19/clnn/2087547

About Clene

关于克莱恩

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

Clene Inc.（纳斯达克股票代码：CLNN）（及其子公司“Clene”）及其合资子公司Clene Nanomedicine Inc.是一家临床后期生物制药公司，致力于改善线粒体健康和保护神经元功能以治疗神经退行性疾病，包括肌萎缩侧索硬化症，帕金森病和多发性硬化症。

CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook..

CNM-Au8®是Clene Nanomedicine，Inc。的联邦注册商标。该公司位于犹他州盐湖城，在马里兰州设有研发和制造业务。欲了解更多信息，请访问www.clene.com或在Twitter，LinkedIn和Facebook上关注我们。。

Contacts:

联络：

Media Contact

媒体联系

Ignacio Guerrero-Ros, Ph.D., or David Schull

伊格纳西奥·格雷罗-罗斯博士或大卫·舒尔

Russo Partners, LLC

Russo Partners，LLC

Ignacio.guerrero-ros@russopartnersllc.com

David.schull@russopartnersllc.com

(858) 717-2310